Lupin set to launch generic of seizure drug in U.S.

Drugmaker Lupin on Wednesday said it has initiated launch of Brivaracetam Oral Solution 10 mg/mL in the United States following U.S. Food and Drug Administration (U.S. FDA) approval for its abbreviated new drug application.

Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB Inc. and indicated for treatment of partial-onset seizures in patients 1 month of age and older. The product (RLD Briviact) had an estimated annual sale of $135 million in the U.S, Lupin said, citing IQVIA MAT December 2025 numbers.